Kratom 7‑OH faces state and federal scrutiny

A Pennsylvania bill would ban 7‑hydroxymitragynine (7‑OH) products above 2%, while the FDA has recommended scheduling kratom concentrate and federal agents seized 7‑OH products in Missouri last December.

I use a concentrated kratom compound called 7‑hydroxymitragynine (7‑OH) to manage long‑standing pain and related symptoms, and I report that it has helped reduce other prescription medications. At the same time, lawmakers and federal agencies have taken steps to restrict kratom and 7‑OH. Those actions have prompted concern among people who use the compound for symptom relief. Known developments: - Pennsylvania state Sen. Tracy Pennycuick introduced legislation to ban 7‑OH products with a concentration above 2%. - The Food and Drug Administration recommended scheduling kratom concentrate under the Controlled Substances Act in July, as reported. - In December, the U.S. Marshals Service raided three firms in Missouri and seized 7‑OH products reported as worth more than $1 million. - The ultimate federal or state regulatory outcomes and any final legal steps are undetermined at this time. Summary: The reporting describes both personal use of 7‑OH for chronic pain and a series of government actions that could limit access, including state legislation, an FDA scheduling recommendation, and federal seizures. Undetermined at this time.